Updates on immunotherapy for colorectal cancer

Aparna Kalyan*, Sheetal Kircher, Hiral Shah, Mary Mulcahy, Al Benson

*Corresponding author for this work

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Despite significant advances in standard of care therapies, the 5-year survival rate for metastatic colorectal cancer (CRC) remains around 12%. Immunotherapy has not provided the stellar advances in colorectal cancer that has been seen in other malignancies. Immunotherapy appears to play a pivotal role in microsatellite unstable CRC tumors where the response rates are profound. These results have led to FDA approval of pembrolizumab for MSI-H CRC tumors. Additional research into several new immune agents including IDO inhibitors, vaccine therapy and combinatorial agents are being evaluated for CRC. This review will provide an overview of the approaches currently being investigated.

Original languageEnglish (US)
Pages (from-to)160-169
Number of pages10
JournalJournal of Gastrointestinal Oncology
Volume9
Issue number1
DOIs
StatePublished - Feb 1 2018

Fingerprint

Immunotherapy
Colorectal Neoplasms
Active Immunotherapy
Standard of Care
Microsatellite Repeats
Research
Neoplasms

Keywords

  • Colorectal cancer (CRC)
  • Immunotherapy
  • Microsatellite instability (MSI)
  • Vaccine therapy

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

@article{b5f886472417485f919b12506fc52742,
title = "Updates on immunotherapy for colorectal cancer",
abstract = "Despite significant advances in standard of care therapies, the 5-year survival rate for metastatic colorectal cancer (CRC) remains around 12{\%}. Immunotherapy has not provided the stellar advances in colorectal cancer that has been seen in other malignancies. Immunotherapy appears to play a pivotal role in microsatellite unstable CRC tumors where the response rates are profound. These results have led to FDA approval of pembrolizumab for MSI-H CRC tumors. Additional research into several new immune agents including IDO inhibitors, vaccine therapy and combinatorial agents are being evaluated for CRC. This review will provide an overview of the approaches currently being investigated.",
keywords = "Colorectal cancer (CRC), Immunotherapy, Microsatellite instability (MSI), Vaccine therapy",
author = "Aparna Kalyan and Sheetal Kircher and Hiral Shah and Mary Mulcahy and Al Benson",
year = "2018",
month = "2",
day = "1",
doi = "10.21037/jgo.2018.01.17",
language = "English (US)",
volume = "9",
pages = "160--169",
journal = "Journal of Gastrointestinal Oncology",
issn = "2078-6891",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "1",

}

Updates on immunotherapy for colorectal cancer. / Kalyan, Aparna; Kircher, Sheetal; Shah, Hiral; Mulcahy, Mary; Benson, Al.

In: Journal of Gastrointestinal Oncology, Vol. 9, No. 1, 01.02.2018, p. 160-169.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Updates on immunotherapy for colorectal cancer

AU - Kalyan, Aparna

AU - Kircher, Sheetal

AU - Shah, Hiral

AU - Mulcahy, Mary

AU - Benson, Al

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Despite significant advances in standard of care therapies, the 5-year survival rate for metastatic colorectal cancer (CRC) remains around 12%. Immunotherapy has not provided the stellar advances in colorectal cancer that has been seen in other malignancies. Immunotherapy appears to play a pivotal role in microsatellite unstable CRC tumors where the response rates are profound. These results have led to FDA approval of pembrolizumab for MSI-H CRC tumors. Additional research into several new immune agents including IDO inhibitors, vaccine therapy and combinatorial agents are being evaluated for CRC. This review will provide an overview of the approaches currently being investigated.

AB - Despite significant advances in standard of care therapies, the 5-year survival rate for metastatic colorectal cancer (CRC) remains around 12%. Immunotherapy has not provided the stellar advances in colorectal cancer that has been seen in other malignancies. Immunotherapy appears to play a pivotal role in microsatellite unstable CRC tumors where the response rates are profound. These results have led to FDA approval of pembrolizumab for MSI-H CRC tumors. Additional research into several new immune agents including IDO inhibitors, vaccine therapy and combinatorial agents are being evaluated for CRC. This review will provide an overview of the approaches currently being investigated.

KW - Colorectal cancer (CRC)

KW - Immunotherapy

KW - Microsatellite instability (MSI)

KW - Vaccine therapy

UR - http://www.scopus.com/inward/record.url?scp=85041718040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041718040&partnerID=8YFLogxK

U2 - 10.21037/jgo.2018.01.17

DO - 10.21037/jgo.2018.01.17

M3 - Review article

VL - 9

SP - 160

EP - 169

JO - Journal of Gastrointestinal Oncology

JF - Journal of Gastrointestinal Oncology

SN - 2078-6891

IS - 1

ER -